Compass Therapeutics, Inc. 1Q 2026: Revenue ($18.76M), EPS ($0.1) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
Compass Therapeutics, Inc. reported its 1Q 2026 results, showing a revenue of $18.76M and a net loss of $18.32M, reflecting a year-over-year increase in losses. The company achieved a clinical milestone with its lead candidate, Tovecimig, in a biliary tract cancer study and received FDA Orphan Drug Designation. The financial position remains strong, with cash expected to support operations until 2028, despite a 41% rise in G&A expenses. The company is advancing multiple antibody programs and preparing for regulatory engagement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments